Our Leadership

Our Leadership

Our focus is to achieve our mission and fulfill our vision.
That’s what drives us.

Our focus is to achieve our mission and fulfill our vision.
That’s what drives us.

Marco Boorsma, PhD
Director
Marco Boorsma, PhD

Marco joined the Forbion team in 2007 and is currently General Partner at Forbion. Marco has a key role in the investment team with focus on biopharma and a special interest to bring his background in molecular biology, operational and business development experience from both small and large businesses to the portfolio. He currently serves on the boards of Inflazome, Escalier Biosciences, NorthSea Therapeutics, Milestone Pharmaceuticals (listed on NASDAQ, $MIST), enGene, and RSPR Pharma and is observer to the board of Oxyrane.

Marco was instrumental in the start-up of Dezima and served on its Board until Dezima was sold to Amgen for up to USD1.5Bn in 2015. Marco also served on the Board of Akarna, which was sold to Allergan for up to USD 1Bn in 2016, and on the board Prexton Therapeutics that was sold to Lundbeck in 2018 for up to USD 1.1Bn. Marco was observer to the Board of Exosome Diagnostics that was sold to Bio-Techne for up to USD 575m.

Marco Boorsma, PhD
Director
Marco Boorsma, PhD

Marco joined the Forbion team in 2007 and is currently General Partner at Forbion. Marco has a key role in the investment team with focus on biopharma and a special interest to bring his background in molecular biology, operational and business development experience from both small and large businesses to the portfolio. He currently serves on the boards of Inflazome, Escalier Biosciences, NorthSea Therapeutics, Milestone Pharmaceuticals (listed on NASDAQ, $MIST), enGene, and RSPR Pharma and is observer to the board of Oxyrane.

Marco was instrumental in the start-up of Dezima and served on its Board until Dezima was sold to Amgen for up to USD1.5Bn in 2015. Marco also served on the Board of Akarna, which was sold to Allergan for up to USD 1Bn in 2016, and on the board Prexton Therapeutics that was sold to Lundbeck in 2018 for up to USD 1.1Bn. Marco was observer to the Board of Exosome Diagnostics that was sold to Bio-Techne for up to USD 575m.